Lab Reference Library / LH (Luteinizing Hormone) Hormones & Reproductive

LH (Luteinizing Hormone)

LH · Luteinizing Hormone · Lutropin

Reference range, optimal functional medicine levels, and why LH is the pituitary signal triggering ovulation in women and testosterone production in men, how the LH-to-FSH ratio identifies PCOS, how low LH distinguishes central from primary hypogonadism, and why cycle-day timing is essential for accurate LH interpretation.

Pituitary GonadotropinOvulation Trigger

Women FM (Day 3)2 to 12 mIU/mL

Mid-Cycle Surge25 to 40+ mIU/mL

Men FM Optimal1.7 to 8 mIU/mL

Postmenopause15 to 60 mIU/mL

← Back to Lab Reference Library

Category: Hormones & Reproductive | Also known as: Luteinizing Hormone, LH, Lutropin

1. What This Test Measures

LH (luteinizing hormone) is a glycoprotein gonadotropin produced by gonadotroph cells in the anterior pituitary gland, released in pulsatile bursts driven by hypothalamic GnRH (gonadotropin-releasing hormone) secretion. LH shares a common alpha subunit with FSH, TSH, and hCG, differing only in its beta subunit, which confers receptor specificity. In women, LH has two distinct roles: it stimulates theca cells in the ovarian follicle to produce androgens (particularly androstenedione and testosterone) that are then converted to estradiol by granulosa cell aromatase, and it triggers the mid-cycle LH surge that initiates ovulation approximately 36 to 48 hours after surge onset. In men, LH acts on Leydig cells in the testicular interstitium to stimulate testosterone biosynthesis through cAMP-mediated activation of steroidogenic enzymes including CYP11A1, CYP17A1, and 17-beta-HSD.

The pulsatile nature of LH secretion is clinically important. GnRH is released from the hypothalamic arcuate nucleus in discrete pulses, and the frequency and amplitude of these pulses determine the ratio of LH to FSH released from the pituitary. High-frequency GnRH pulses preferentially stimulate LH over FSH, while low-frequency pulses favor FSH. This differential sensitivity explains the LH:FSH ratio abnormalities seen in PCOS (where GnRH pulse frequency is pathologically increased) and in hypothalamic amenorrhea (where GnRH pulsatility is suppressed, reducing both LH and FSH but with disproportionate LH suppression).

LH is measured as a routine component of reproductive hormone panels in functional medicine for assessment of ovulatory function, PCOS evaluation, hypogonadism characterization, monitoring during hormone therapy, and perimenopausal transition assessment. Like FSH, the clinical interpretation of LH depends critically on the cycle day of the draw and concurrent measurement of estradiol, progesterone, and FSH.

2. Reference Range and Cycle-Phase Interpretation

Cycle Phase or Clinical State	Standard Reference	FM Optimal / Interpretation
Early follicular (Days 2 to 4)	2.0 to 15.0 mIU/mL	FM optimal 2 to 8 mIU/mL; elevated may indicate PCOS or early ovarian failure
Mid-cycle LH surge	22.0 to 105.0 mIU/mL	Surge triggers ovulation; timing determines fertile window; OPK detection practical
Luteal phase	0.6 to 19.3 mIU/mL	Falls after ovulation; not useful for PCOS or reserve evaluation
Postmenopause	15.9 to 54.0 mIU/mL	Persistently elevated with FSH; confirms ovarian failure in menopausal transition
Men (adult)	1.7 to 8.6 mIU/mL	FM optimal 3 to 8 mIU/mL; low with low T = central hypogonadism; high with low T = primary failure
PCOS early follicular	Often above 10 to 12 mIU/mL	LH:FSH ratio above 2:1 supports PCOS in the context of clinical features

LH has a shorter half-life than FSH (approximately 20 minutes vs 4 hours) and shows greater pulsatile variability; a single measurement may not represent the true mean LH. In research settings, three samples drawn 20 minutes apart are averaged for more accurate mean LH determination. In clinical practice, the cycle-phase context and LH:FSH ratio provide more actionable information than the absolute LH value alone. Single elevated or low LH values should be interpreted with appropriate uncertainty and confirmed with concurrent FSH and estradiol.

3. LH in PCOS: The Neuroendocrine Mechanism

The pathological LH hypersecretion in PCOS is not a primary pituitary problem but a consequence of hypothalamic GnRH pulse dysregulation driven by a combination of insulin resistance, androgen excess, and impaired progesterone feedback.

In normal reproductive physiology, progesterone produced after ovulation slows GnRH pulse frequency during the luteal phase, maintaining the FSH-favoring low-frequency pulse pattern. In PCOS, absent or insufficient ovulation means progesterone is not produced, so the GnRH pulse frequency remains high throughout the cycle, continuously favoring LH over FSH production. The resulting chronically elevated LH drives excess androgen production from ovarian theca cells (through LH receptor stimulation), and the relative FSH deficiency impairs follicle maturation and perpetuates anovulation. The androgens produced are then converted by adipose aromatase to estrogens that provide positive estradiol feedback to the pituitary rather than the normal mid-cycle surge feedback, further destabilizing the hormonal cycle. This creates a self-perpetuating neuroendocrine loop where anovulation drives more LH, more androgens, and continued anovulation.

Insulin resistance amplifies this pattern through insulin receptor signaling on ovarian theca cells that potentiates LH-driven androgen production, explaining why insulin sensitization with metformin, inositol, or GLP-1 therapies often partially restores ovulatory function in PCOS patients by reducing the insulin amplification of the LH-androgen axis.

4. LH Patterns in Male Hypogonadism

High LH with Low Testosterone: Primary Failure

Pattern interpretation: LH above 10 mIU/mL with testosterone below 300 ng/dL indicates the pituitary is sending maximum stimulation but the testes cannot respond; the problem is in the testes (primary hypogonadism or hypergonadotropic hypogonadism)
Common causes: Klinefelter syndrome (47,XXY), bilateral orchitis (mumps), bilateral varicocele, gonadotoxic chemotherapy or radiation, bilateral cryptorchidism, autoimmune orchitis, anorchia, and idiopathic tubular failure
Treatment implications: clomiphene and hCG therapy are ineffective because the testes cannot respond to gonadotropin stimulation; TRT is required; fertility preservation requires testicular sperm extraction (TESE) with cryopreservation; sperm banking should be discussed with young men before gonadotoxic therapy
FSH concurrent interpretation: primary testicular failure typically elevates both LH and FSH simultaneously; selective FSH elevation with normal LH may indicate Sertoli cell-specific damage (spermatogenesis impaired but testosterone production relatively preserved); selective LH elevation is uncommon and may warrant investigation for Leydig cell-specific dysfunction

Low LH with Low Testosterone: Central Hypogonadism

Pattern interpretation: LH below 2 mIU/mL (or inappropriately normal, below 5 mIU/mL) with testosterone below 300 ng/dL indicates insufficient pituitary gonadotropin drive; the testes are potentially normal but are not receiving adequate stimulation (secondary or hypogonadotropic hypogonadism)
Common causes in functional medicine practice: obesity and leptin resistance (suppresses hypothalamic GnRH pulsatility); chronic exogenous testosterone or anabolic steroid use (most common iatrogenic cause; suppresses HPG axis through negative feedback); opioid use (opioids suppress GnRH in the hypothalamus); hyperprolactinemia from pituitary adenoma; Kallmann syndrome; severe caloric restriction or malnutrition
Fertility-preserving treatment: clomiphene citrate (25 to 50mg every other day) blocks hypothalamic estrogen receptors, reducing negative feedback and increasing GnRH drive, thereby stimulating LH and FSH release; LH rises, stimulating testicular Leydig cell testosterone production; FSH rises, supporting spermatogenesis; both testosterone and fertility are preserved simultaneously; FSH and LH monitoring during clomiphene therapy confirms adequate axis stimulation
Evaluation for pituitary lesion: serum prolactin should be measured in all men with low LH and low testosterone; prolactinoma is the most common pituitary tumor and a reversible cause of secondary hypogonadism that responds to dopamine agonist therapy without TRT

5. LH During Hormone Therapy

LH on exogenous testosterone in men: testosterone provides potent negative feedback to the hypothalamus and pituitary; LH falls to below 1 mIU/mL on adequate TRT and is expected to remain suppressed during therapy; a rising LH while on TRT suggests insufficient dose, poor absorption, or patient non-compliance rather than a new hormonal problem; concurrent testosterone measurement confirms whether the LH suppression failure reflects inadequate systemic testosterone levels
LH during clomiphene therapy in men: clomiphene blocks estrogen receptor feedback at the hypothalamic-pituitary level, allowing LH (and FSH) to rise; serial LH monitoring at 4 to 6 weeks after initiation confirms adequate axis response; target LH 6 to 12 mIU/mL on clomiphene therapy alongside rising testosterone; LH above 15 mIU/mL may indicate excessive stimulation requiring dose reduction
LH on HRT in postmenopausal women: administered estrogen suppresses LH through negative feedback in a dose-dependent manner; LH falling from very high postmenopausal values (above 40 mIU/mL) toward 10 to 20 mIU/mL on HRT indicates adequate systemic estrogen replacement; persistently very high LH despite HRT suggests insufficient estrogen dose or poor absorption from transdermal or compounded preparations
LH after TRT discontinuation: after stopping exogenous testosterone, the HPG axis recovery timeline depends on duration and intensity of prior testosterone use; LH typically begins to recover within 3 to 6 months of complete TRT discontinuation; FSH and LH serial monitoring every 4 to 6 weeks during TRT washout tracks axis recovery; hCG therapy during TRT discontinuation can accelerate Leydig cell stimulation and shorten recovery time

6. How to Support Healthy LH Function

Optimize GnRH Pulsatility

Address obesity and insulin resistance: the most common reversible cause of impaired LH pulsatility in both men and women; leptin resistance from obesity suppresses hypothalamic GnRH neurons; insulin sensitization and weight management restore GnRH pulsatility in many cases
Adequate caloric intake: hypothalamic amenorrhea from caloric restriction or excessive exercise suppresses GnRH and therefore LH; restoring energy balance is the primary and often only required intervention; minimum energy availability of 30 kcal per kg of fat-free mass per day is the threshold below which GnRH suppression reliably occurs
Sleep quality and circadian alignment: LH is released in a circadian-modulated pulsatile pattern with nocturnal augmentation particularly in puberty; chronic sleep deprivation and circadian disruption impair the hypothalamic regulatory circuits that drive optimal GnRH and LH secretion
Manage chronic stress and HPA axis dysregulation: CRH (corticotropin-releasing hormone) from the hypothalamus during stress directly suppresses GnRH neurons through CRH receptor signaling; chronic psychological and physiological stress impairs LH pulsatility through this mechanism
Reduce opioid burden: opioids (both prescription and endogenous from chronic stress-driven beta-endorphin elevation) suppress GnRH pulsatility; opioid-induced hypogonadism requires dose reduction or switching to buprenorphine (which has less GnRH suppressive effect) alongside monitoring of the HPG axis recovery

PCOS LH Management

Inositol (myo-inositol 2,000mg and D-chiro-inositol 50mg twice daily): restores insulin receptor signaling in the ovary, reducing the insulin amplification of LH-driven androgen production; improves menstrual regularity and reduces LH amplitude in multiple clinical studies; the 40:1 myo-to-D-chiro ratio matches physiological tissue concentrations
Metformin (500 to 1,500mg daily) or berberine (500mg three times daily): insulin sensitizers that reduce the hyperinsulinemia amplifying LH-driven ovarian androgen production; partial ovulatory function restoration in PCOS in multiple RCTs; metformin second-line after lifestyle; berberine comparable to metformin in several head-to-head trials
Weight management: even 5 to 10% body weight reduction in overweight PCOS patients often restores ovulatory cycles through reduced insulin resistance and adipose aromatase-driven estrogen production; both reduce the LH-stimulating positive feedback from estrone
Progesterone therapy (cyclic): oral micronized progesterone for 10 to 14 days monthly in women with PCOS and absent ovulation restores the progesterone-mediated GnRH pulse frequency slowdown that is absent due to anovulation; the lowered pulse frequency favors FSH over LH, partially normalizing the LH:FSH ratio

Supporting Labs and Panel Context

LH:FSH ratio calculation: always calculate the early follicular phase LH:FSH ratio; above 2:1 in a woman with irregular cycles and androgen excess supports PCOS; above 3:1 is strongly suggestive; the ratio is more informative than either value alone for PCOS screening
Prolactin concurrent measurement: hyperprolactinemia suppresses GnRH and produces low LH and FSH with menstrual irregularity or amenorrhea; prolactinoma is a reversible cause of apparent PCOS-like picture; prolactin should be measured in all women presenting with irregular cycles and LH abnormalities
AMH and antral follicle count: in women with PCOS, AMH is typically elevated (above 3 to 4 ng/mL) from the large cohort of small antral follicles characteristic of polycystic ovarian morphology; elevated AMH with elevated LH and elevated androgens is the biochemical triad of PCOS; antral follicle count above 20 per ovary on ultrasound confirms the ovarian morphological component
Testosterone and free testosterone: LH-driven androgen excess in PCOS is best captured by free testosterone (calculated or measured by equilibrium dialysis); total testosterone may be normal while free testosterone is elevated from low SHBG; both should be measured when the LH:FSH ratio suggests PCOS
17-hydroxyprogesterone: rule out non-classical congenital adrenal hyperplasia (NCAH) presenting similarly to PCOS; morning follicular phase 17-OHP above 2 ng/mL warrants ACTH stimulation testing; NCAH is the most common adrenal cause of androgen excess and can mimic PCOS clinically and biochemically

7. Related Lab Tests

FSHAlways Measured Alongside LH; LH:FSH Ratio Is the Key PCOS Diagnostic Metric

→

EstradiolNegative Feedback Regulator of LH; Must Be Concurrent With LH Draw

→

ProlactinSuppresses GnRH and LH; Rule Out Hyperprolactinemia in LH Abnormalities

→

TestosteroneLH Drives Testosterone Production in Men; Companion in Hypogonadism Evaluation

→

AMHElevated AMH With High LH Ratio Is the PCOS Biochemical Signature

→

ProgesteroneLuteal Progesterone Measurement Confirms Whether the LH-Triggered Ovulation Occurred

→

8. Clinical Perspective

Clinical Perspective

LH is the hormone that explains the neuroendocrine mechanism of PCOS in a way that makes the condition make sense to patients, which changes how they engage with treatment. When I show a 29-year-old woman with irregular cycles and acne that her LH is 14 mIU/mL and her FSH is 4 mIU/mL on day 3, and explain that her hypothalamus is pulsing at a frequency that preferentially drives LH over FSH because there is no progesterone feedback from ovulation to slow it down, and that this elevated LH is driving her theca cells to overproduce androgens that are causing her acne and hair loss, the condition becomes a coherent system rather than a collection of unrelated symptoms. The treatment plan follows logically from the mechanism: restore insulin sensitivity to reduce the insulin amplification of LH-driven androgen production, use inositol to target the ovarian insulin receptor specifically, consider cyclic progesterone to restore the GnRH pulse frequency regulation that requires ovulation to occur naturally. Patients who understand the mechanism follow through with treatment because the connection between the intervention and the problem is explicit. That is what evidence-forward endocrinology looks like in the functional medicine framework.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

What does elevated LH mean in women?

Elevated LH in women has different significance depending on the cycle timing and clinical context. At mid-cycle, a sharp LH surge (typically 25 to 40 mIU/mL or more) triggers ovulation 36 to 48 hours later and is the normal and expected hormonal event that home ovulation predictor kits detect. Outside the mid-cycle window, persistently elevated LH (above 12 mIU/mL in the follicular or luteal phase) suggests either PCOS (where the pulsatile LH amplitude is increased, producing chronic LH elevation that drives excess androgen production), or ovarian failure (where LH rises alongside FSH from absent ovarian feedback), or menopause (where both LH and FSH are chronically and markedly elevated).

What is the LH:FSH ratio and why does it matter for PCOS?

The LH-to-FSH ratio is a diagnostic clue for polycystic ovarian syndrome. In the early follicular phase of normal cycles, LH and FSH are approximately equal (ratio near 1:1). In PCOS, the hypothalamic GnRH pulse generator operates at a higher frequency and amplitude than normal, preferentially stimulating LH over FSH. This produces chronically elevated LH relative to FSH, with an LH:FSH ratio above 2:1 and often above 3:1. The elevated LH drives excess androgen production from ovarian theca cells (through LH receptor activation), while the relatively lower FSH impairs normal follicular maturation and ovulation. An early follicular phase LH:FSH ratio above 2:1 in a woman with irregular cycles and elevated androgens supports the PCOS diagnosis even when individual LH and FSH values are in the normal reference range.

What does low LH indicate in men?

Low LH in men, particularly when accompanied by low testosterone, indicates secondary (central) hypogonadism: the pituitary is not producing adequate LH to stimulate testicular testosterone production. Common causes include obesity-driven hypothalamic suppression, chronic exogenous testosterone or anabolic steroid use (which suppresses the HPG axis), hyperprolactinemia from a pituitary adenoma, Kallmann syndrome (congenital GnRH deficiency), opioid use (opioids suppress GnRH pulsatility), and pituitary infiltrative or destructive disease. The clinical distinction between low LH (central problem) and high LH (testicular problem) with low testosterone determines whether clomiphene, hCG, or TRT is the appropriate intervention.

How is LH used to time ovulation for fertility?

The LH surge, a rapid rise in serum LH to typically 25 to 40 mIU/mL or more above baseline, triggers the resumption of meiosis in the dominant follicle and initiates the cascade leading to follicle rupture and egg release approximately 36 to 48 hours later. Commercially available urine LH surge detection kits (ovulation predictor kits) detect this surge and are the most practical method for home ovulation timing. Serum LH measurement is used in clinical fertility monitoring when more precise timing is needed for intrauterine insemination (IUI) or intercourse timing. Serial serum LH every 8 to 12 hours during the mid-cycle window provides the most accurate identification of surge onset. The IUI or timed intercourse should occur within 24 to 36 hours of detected LH surge for optimal fertilization timing.

What happens to LH during perimenopause and after menopause?

LH rises progressively through the perimenopausal transition alongside FSH, as declining ovarian estradiol and inhibin B reduce the negative feedback that suppresses pituitary gonadotropin secretion. In early perimenopause, LH may be variably elevated with maintained cycles. In late perimenopause, LH rises more consistently. After menopause, both LH and FSH reach their highest values (LH typically 15 to 60 mIU/mL postmenopausally), and this elevation persists because there are no ovarian follicles remaining to provide inhibin B or estradiol feedback. On hormone replacement therapy, LH falls as administered estrogen provides the negative feedback that was absent with ovarian failure, partially restoring hypothalamic-pituitary regulation. LH on HRT is sometimes used to assess adequacy of estrogen replacement dosing.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

LH is the neuroendocrine key to understanding PCOS, hypogonadism classification, and ovulatory function. The LH:FSH ratio and cycle-day timing transform it from a number into a clinical story.

LH is a core component of every reproductive hormone evaluation at The Lamkin Clinic. Schedule a consultation for a comprehensive gonadotropin assessment and personalized hormone optimization plan.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.